Pilot study by Brigham investigators finds that an innovative care-delivery program helped 81 percent of participants achieve blood pressure control in seven weeks
Hypertension, or high blood pressure, is a widespread clinical problem affecting nearly half of all adults. Despite the serious consequences that can result from hypertension, which puts patients at increased risk for heart attacks, strokes and other cardiovascular events, elevated blood pressures often remain untreated or undertreated for years, and the control rate for hypertension hovers at just 50 percent. Seeing opportunities for improvement, innovators and clinicians at Brigham and Women’s Hospital have developed a new home-based, care-delivery program aimed to improve hypertension control rates quickly and at significantly lower cost than traditional, office-based blood pressure programs. The new approach, piloted among 130 participants, helped 81 percent of patients bring their blood pressures under control in, on average, just seven weeks. The results of the pilot study are published this week in Clinical Cardiology.
“This is a striking result, especially given the very short time frame in which control was reached: an average of seven weeks,” said corresponding author Naomi Fisher, MD, director of the Hypertension Service and Hypertension Specialty Clinic at the Brigham. “There are a few notable health care systems that have matched or exceeded this control rate, but most clinical practices do not approach this rate of success.”
To overcome some of the challenges that clinical practices face, Fisher and colleagues combined several innovative strategies to create their program. Enrolled participants each received a Bluetooth-enabled blood pressure device that could automatically transmit the blood pressure measurements patients took at home into their electronic medical records. Patients had easy and frequent access to “patient navigators”–non-physicians who had been trained to use a clinical algorithm developed by hypertension specialists. The program enabled rapid assessment and medication dosage adjustments for the patients.
The pilot was conducted as a prospective cohort study. The team enrolled 130 patients whose blood pressure was uncontrolled (greater than 140/90 mmHg). Patients were recruited from two clinics to test efficacy in two settings: a Brigham primary care clinic (800 Huntington Ave.), and the Brigham’s Watkins Cardiovascular Clinic. All adults were eligible except pregnant women and those with advanced kidney disease. Enrolled patients were given a Bluetooth-enabled blood pressure device and taught how to use it. Patients were instructed to measure their blood pressure at home twice daily in duplicate. Medication adjustments were made every two weeks until home blood pressure was controlled at <135/85 mmHg.
The team’s next step will be to scale up the program to test its generalizability and sustainability. With this approach, the team anticipates significant cost effectiveness and cost savings, in addition to the prevention of cardiovascular events and death from treating hypertension more intensively in men and women.
“The time-honored model of treating hypertension via traditional visits to the doctor is neither effective nor sustainable,” said Fisher. “Development of innovative solutions to manage hypertension effectively and efficiently, and thus reduce the cardiovascular risk burden in larger populations, is critical. Organizations can and should develop and adopt innovative technologies to create sustainable solutions for the control of hypertension.”
The Latest on: Hypertension
via Google News
The Latest on: Hypertension
- Blood Pressure Medication Recall 2021: Hypertension Drug Recalled Over Cancer Riskson October 14, 2021 at 10:52 am
In another recall over cancer-causing impurity levels, Lupin Pharmaceutical has recalled several batches of its Irbesartan tablets and Irbesartan and Hydrochlorothiazide tablets because ...
- Lupin recalls 2 hypertension drugs in US due to potential impurityon October 14, 2021 at 6:44 am
Drug firm Lupin on Thursday said its US-based arm is voluntarily recalling all batches of two hypertension drugs due to potential presence of a substance that could cause cancer.
- Janssen Showcases Commitment to Advancing Scientific Innovation in Pulmonary Arterial Hypertension (PAH) at CHEST 2021 Annual Meetingon October 14, 2021 at 4:13 am
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 11* abstracts highlighting data from its pulmonary hypertension (PH) portfolio will be presented at CHEST 2021, the annual ...
- Hypertension - Newson October 13, 2021 at 1:05 pm
Renal Denervation Hits the Headlines Renal denervation for resistant hypertension made headlines around the world this week, as the one-year results of a trial with the Symplicity catheter were ...
- UAB researcher awarded NIH grant to research peer support for women living with hypertension and HIVon October 13, 2021 at 10:09 am
Crockett’s K23 research project focuses on the adaptation of a behavioral physical activity intervention with peer support for women with HIV and co-occurring hypertension. The NIH award gives ...
- Shorter Pregnancies Mean Higher Lifelong Hypertension Riskon October 13, 2021 at 8:06 am
Delivering a child preterm carried lifelong risk for hypertension, a large population-based study showed. Among more than 2 million women in Sweden, delivery before 37 weeks' gestation was ...
- Hypertension at age 35–44 linked to higher dementia riskon October 7, 2021 at 4:36 am
A new study finds that people diagnosed with hypertension between ages 34 and 44 years are more likely to develop dementia than those without hypertension.
- High blood pressure: The six lifestyle changes to help you avoid hypertensionon October 6, 2021 at 2:32 am
IF you’ve got high blood pressure you might not even notice it – as the condition rarely has symptoms. Around a third of adults in the UK have high blood pressure but will have no idea ...
- Higher Odds of Hypertension Seen in Older Women, Younger Menon October 3, 2021 at 10:00 am
New research presented at the AHA Hypertension Scientific Sessions 2021 showed that men aged 20 to 49 years and women 70 and older both had a greater risk of hypertension.
- There's No Place Like Home to Diagnose Hypertensionon October 1, 2021 at 12:51 pm
From a patient perspective, home blood pressure (BP) monitoring is the most acceptable method to track BP to confirm or refute a diagnosis of hypertension, a new study shows.
via Bing News